Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.

Morgan MM, Arendt LM, Alarid ET, Beebe DJ, Johnson BP.

FASEB J. 2019 Apr 19:fj201802347RRR. doi: 10.1096/fj.201802347RRR. [Epub ahead of print]

PMID:
31002529
2.

Grainyhead-like Protein 2: The Emerging Role in Hormone-Dependent Cancers and Epigenetics.

Reese RM, Harrison MM, Alarid ET.

Endocrinology. 2019 May 1;160(5):1275-1288. doi: 10.1210/en.2019-00213.

PMID:
30958537
3.

The Phosphorylated Estrogen Receptor α (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2.

Helzer KT, Szatkowski Ozers M, Meyer MB, Benkusky NA, Solodin N, Reese RM, Warren CL, Pike JW, Alarid ET.

Mol Cell Biol. 2019 Jan 16;39(3). pii: e00417-18. doi: 10.1128/MCB.00417-18. Print 2019 Feb 1.

PMID:
30455249
4.

Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.

Morgan MM, Livingston MK, Warrick JW, Stanek EM, Alarid ET, Beebe DJ, Johnson BP.

Sci Rep. 2018 May 8;8(1):7139. doi: 10.1038/s41598-018-25461-1.

5.

17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes.

Jallow F, Brockman JL, Helzer KT, Rugowski DE, Goffin V, Alarid ET, Schuler LA.

J Endocr Soc. 2018 Feb 26;2(3):293-309. doi: 10.1210/js.2017-00399. eCollection 2018 Mar 1.

6.

Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments.

Regier MC, Maccoux LJ, Weinberger EM, Regehr KJ, Berry SM, Beebe DJ, Alarid ET.

Biomed Microdevices. 2016 Aug;18(4):70. doi: 10.1007/s10544-016-0083-x.

7.

Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Morgan MM, Johnson BP, Livingston MK, Schuler LA, Alarid ET, Sung KE, Beebe DJ.

Pharmacol Ther. 2016 Sep;165:79-92. doi: 10.1016/j.pharmthera.2016.05.007. Epub 2016 May 21. Review.

8.

Progress towards understanding heterotypic interactions in multi-culture models of breast cancer.

Regier MC, Alarid ET, Beebe DJ.

Integr Biol (Camb). 2016 Jun 13;8(6):684-92. doi: 10.1039/c6ib00001k. Epub 2016 Apr 21. Review.

9.

Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.

Helzer KT, Hooper C, Miyamoto S, Alarid ET.

J Mol Endocrinol. 2015 Jun;54(3):R151-67. doi: 10.1530/JME-14-0308. Epub 2015 May 5. Review.

10.

Peptidylprolyl Isomerase Pin1 Directly Enhances the DNA Binding Functions of Estrogen Receptor α.

Rajbhandari P, Ozers MS, Solodin NM, Warren CL, Alarid ET.

J Biol Chem. 2015 May 29;290(22):13749-62. doi: 10.1074/jbc.M114.621698. Epub 2015 Apr 12.

11.

A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Tian D, Solodin NM, Rajbhandari P, Bjorklund K, Alarid ET, Kreeger PK.

FASEB J. 2015 May;29(5):2022-31. doi: 10.1096/fj.14-265637. Epub 2015 Feb 3.

12.

Streamlining gene expression analysis: integration of co-culture and mRNA purification.

Berry SM, Singh C, Lang JD, Strotman LN, Alarid ET, Beebe DJ.

Integr Biol (Camb). 2014 Feb;6(2):224-31. doi: 10.1039/c3ib40136g.

13.

The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.

Powers GL, Rajbhandari P, Solodin NM, Bickford B, Alarid ET.

PLoS One. 2013 Dec 5;8(12):e81110. doi: 10.1371/journal.pone.0081110. eCollection 2013.

14.

Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity.

Lang JD, Berry SM, Powers GL, Beebe DJ, Alarid ET.

Integr Biol (Camb). 2013 May;5(5):807-16. doi: 10.1039/c3ib20265h.

15.

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.

Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET.

Oncogene. 2014 Mar 13;33(11):1438-47. doi: 10.1038/onc.2013.78. Epub 2013 Apr 1.

16.

Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Rajbhandari P, Finn G, Solodin NM, Singarapu KK, Sahu SC, Markley JL, Kadunc KJ, Ellison-Zelski SJ, Kariagina A, Haslam SZ, Lu KP, Alarid ET.

Mol Cell Biol. 2012 Jan;32(2):445-57. doi: 10.1128/MCB.06073-11. Epub 2011 Nov 7.

17.

Purification of cell subpopulations via immiscible filtration assisted by surface tension (IFAST).

Berry SM, Strotman LN, Kueck JD, Alarid ET, Beebe DJ.

Biomed Microdevices. 2011 Dec;13(6):1033-42. doi: 10.1007/s10544-011-9573-z.

18.

Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.

Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL.

J Clin Oncol. 2011 Aug 1;29(22):2978-84. doi: 10.1200/JCO.2010.32.9706. Epub 2011 Jun 27.

19.

One-step purification of nucleic acid for gene expression analysis via Immiscible Filtration Assisted by Surface Tension (IFAST).

Berry SM, Alarid ET, Beebe DJ.

Lab Chip. 2011 May 21;11(10):1747-53. doi: 10.1039/c1lc00004g. Epub 2011 Mar 21.

20.
21.

Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET.

Oncogene. 2010 Mar 11;29(10):1509-18. doi: 10.1038/onc.2009.434. Epub 2009 Nov 30.

22.

Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Ellison-Zelski SJ, Solodin NM, Alarid ET.

Mol Cell Biol. 2009 Sep;29(18):4949-58. doi: 10.1128/MCB.00383-09. Epub 2009 Jul 20.

23.

Biological implications of polydimethylsiloxane-based microfluidic cell culture.

Regehr KJ, Domenech M, Koepsel JT, Carver KC, Ellison-Zelski SJ, Murphy WL, Schuler LA, Alarid ET, Beebe DJ.

Lab Chip. 2009 Aug 7;9(15):2132-9. doi: 10.1039/b903043c. Epub 2009 Jun 4. Review.

24.

Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen.

Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET.

J Mol Endocrinol. 2008 Jan;40(1):23-34.

PMID:
18096994
25.

Amping up estrogen receptors in breast cancer.

Fowler AM, Alarid ET.

Breast Cancer Res. 2007;9(4):305. Review.

26.

The DNA binding domain of estrogen receptor alpha is required for high-affinity nuclear interaction induced by estradiol.

Weinberg AL, Carter D, Ahonen M, Alarid ET, Murdoch FE, Fritsch MK.

Biochemistry. 2007 Aug 7;46(31):8933-42. Epub 2007 Jul 14.

PMID:
17630774
28.

Lives and times of nuclear receptors.

Alarid ET.

Mol Endocrinol. 2006 Sep;20(9):1972-81. Epub 2006 Jan 19. Review.

PMID:
16423879
29.

Altered target gene regulation controlled by estrogen receptor-alpha concentration.

Fowler AM, Solodin NM, Valley CC, Alarid ET.

Mol Endocrinol. 2006 Feb;20(2):291-301. Epub 2005 Sep 22.

PMID:
16179380
30.

Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.

Valley CC, Métivier R, Solodin NM, Fowler AM, Mashek MT, Hill L, Alarid ET.

Mol Cell Biol. 2005 Jul;25(13):5417-28.

31.

Nuclear receptor and transcriptional complex cycles.

Fowler AM, Alarid ET.

Sci STKE. 2004 Dec 7;2004(262):tr11.

32.

Dynamic control of nuclear receptor transcription.

Fowler AM, Alarid ET.

Sci STKE. 2004 Oct 26;2004(256):pe51. Review.

PMID:
15507593
33.
35.

Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha.

Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET.

Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E891-8.

36.

Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Alarid ET, Bakopoulos N, Solodin N.

Mol Endocrinol. 1999 Sep;13(9):1522-34.

PMID:
10478843
37.

The thyrotropin beta-subunit gene is repressed by thyroid hormone in a novel thyrotrope cell line, mouse T alphaT1 cells.

Yusta B, Alarid ET, Gordon DF, Ridgway EC, Mellon PL.

Endocrinology. 1998 Nov;139(11):4476-82.

PMID:
9794455
38.

Discrete stages of anterior pituitary differentiation recapitulated in immortalized cell lines.

Alarid ET, Holley S, Hayakawa M, Mellon PL.

Mol Cell Endocrinol. 1998 May 25;140(1-2):25-30.

PMID:
9722164
39.

Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice.

Alarid ET, Windle JJ, Whyte DB, Mellon PL.

Development. 1996 Oct;122(10):3319-29.

41.

Keratinocyte growth factor functions in epithelial induction during seminal vesicle development.

Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, Cunha GR.

Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1074-8.

42.
43.

Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors.

Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA.

J Androl. 1992 Nov-Dec;13(6):465-75. Review.

44.

Evidence suggesting that insulin-like growth factor-I is necessary for the trophic effects of insulin on cartilage growth in vivo.

Alarid ET, Schlechter NL, Russell SM, Nicoll CS.

Endocrinology. 1992 Apr;130(4):2305-9.

PMID:
1547741
45.

Supplemental Content

Loading ...
Support Center